Dr Guy Simpson
Research Fellow Oncology
Qualifications: BSc PhD
Email: g.simpson@surrey.ac.uk
Phone: Work: 01483 68 8600
Room no: 30 PGM 02
Office hours
9am to 5pm Mon-Fri
Further information
Biography
2004 PhD Optimising therapeutic herpes simplex vectors for cancer.
BioVex Ltd/UCL The Windeyer Institute, 46 Cleveland Street, London.
1997 MPhil Human endogenous retroviral particles expressed in the placenta.
Institute of Cancer Research, Chester Beatty Labs, Fulham Road, London.
1988 B.Sc. Honours Degree in Bioanalytical Science (Class IIi).
Kingston Polytechnic, Surrey.
2004-2007 Senior Scientist, UCL (Biovex Ltd), The Windeyer Institute, London.
.
1999-2004 Scientist UCL (Biovex Ltd), The Windeyer Institute, London.
1995-1999 Research Associate, Prof Thomas F. Schulz, University of Liverpool.
•
1989-1995 Scientific Officer, Prof Robin Weiss, Institute of Cancer Research
Research Interests
Viral Vectors
Molecular Biology
Tumour Biology
Gene Therapy
Publications
Journal articles
- . (2012) 'Targeting the HOX/PBX dimer in breast cancer.'. Breast Cancer Res Treat, Netherlands: 136 (2), pp. 389-398.
- .
(2012) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. BRITISH JOURNAL OF CANCER, 106 (3), pp. 496-507.doi: 10.1038/bjc.2011.577
- .
(2011) 'Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.'. BMC Cancer, England: 11Full text is available at: http://epubs.surrey.ac.uk/107390/
Abstract
Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.
- . (2010) 'A Third-Generation Herpesvirus Is Effective Against Gastroesophageal Cancer'. ACADEMIC PRESS INC ELSEVIER SCIENCE JOURNAL OF SURGICAL RESEARCH, 163 (2), pp. 214-220.
- .
(2010) 'The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 18 (12), pp. 2085-2093.doi: 10.1038/mt.2010.189
- .
(2010) 'Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 486 Full text is available at: http://epubs.surrey.ac.uk/713427/
- . (2010) 'Oncolysis using herpes simplex virus type 1 Engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma'. Archives of Otolaryngology - Head and Neck Surgery, 136 (2), pp. 151-158.
- .
(2009) 'Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 15 (19), pp. 6158-6166.Full text is available at: http://epubs.surrey.ac.uk/227160/
- . (2009) 'Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.'. Methods Mol Biol, United States: 542, pp. 551-564.
- .
(2007) 'Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.'. J Gene Med, England: 9 (2), pp. 99-106.doi: 10.1002/jgm.999
- . (2006) 'Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.'. Cancer Res, United States: 66 (9), pp. 4835-4842.
Conference papers
- . (2012) 'Modulation of Regulatory T Cells by Targeting The NFAT-FOXP3 Protein: Protein Interaction'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, North Bethesda, MD: 27th Annual Scientific Meeting of the Society-for-Immunotherapy-of-Cancer (SITC) 35 (9), pp. 775-775.
- . (2011) 'EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.'. JCO, Chicago: ASCO (J Clin Oncol 29: 2011 (suppl; abstr e15528))
- . (2011) 'Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 47-48.
- . (2011) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer (visualised by micro CT)'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 52-53.
- . (2010) 'EN2: A Novel Immunotherapeutic Target for Melanoma'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 891-891.
- . (2010) 'NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER USING A GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS'. ELSEVIER SCIENCE BV EUR UROL SUPPL, 9 (6), pp. 646-646.
- . (2008) 'Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 99-99.
